Citigroup
DMRA

Citigroup’s Damora Therapeutics DMRA Stock Holding History

Citigroup’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Buy
43,419
+32,324
+291% +$783K ﹤0.01% 3355
2026
Q1 		$287K Buy
11,095
+9,968
+884% +$256K ﹤0.01% 3815
2025
Q4 		$25.9K Buy
1,127
+1,084
+2,521% +$18.8K ﹤0.01% 4797
2025
Q3 		$160 Buy
+43
New +$146 ﹤0.01% 5779
2022
Q2 		– Sell
-10
Closed -$1K – 6384
2022
Q1 		$1K Hold
10
– – ﹤0.01% 6165
2021
Q4 		$1K Hold
10
– – ﹤0.01% 5762
2021
Q3 		$1K Hold
10
– – ﹤0.01% 5696
2021
Q2 		$1K Buy
+10
New +$1.36K ﹤0.01% 6032

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Citigroup's DMRA Position: Q2 2026 in Review

Citigroup increased its Damora Therapeutics (DMRA) stake by 291% in Q2 2026, buying an estimated $783K and bringing the position to 43,419 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #3355.

Citigroup first reported a position in DMRA in Q2 2021 and has held it in 8 quarters since. 104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • Citigroup held 43,419 shares of Damora Therapeutics worth $1.13M as of Q2 2026.
  • Citigroup bought 32,324 Damora Therapeutics shares in Q2 2026, an estimated $783K.
  • Damora Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3355 holding.
  • Citigroup first reported a position in Damora Therapeutics in Q2 2021 and has held it in 8 quarters since.
  • 104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.